AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC
NCT06196814
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Efficacy
Interventions
DRUG:
PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
Sponsor
Hunan Province Tumor Hospital